14-3-3 secreted in serum or synovial fluid has been considered as a biomarker for RA diagnosis.161 Clinically, TNFα inhibitors like ADA have been observed to reduce serum 14-3-3η levels in RA patients,160 further suggesting that 14-3-3η may serve as a potential target molecule for RA. This evidence concerns the gene ADA and rheumatoid arthritis.